MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
LC 2 Epimer
CAS:<p>Negative control for LC 2.</p>Formula:C59H71ClFN11O7SColor and Shape:SolidMolecular weight:1132.8YN14
<p>YN14 is a highly potent and selective KRASG12C proteolysis targeting chimera (PROTAC) capable of forming a stable KRASG12C: YN14: VHL ternary complex with low</p>Purity:98%Color and Shape:Odour SolidCC-401
CAS:<p>CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).</p>Formula:C22H24N6OPurity:98%Color and Shape:SolidMolecular weight:388.47Murrayafoline A
CAS:<p>Murrayafoline A is a useful organic compound for research related to life sciences. The catalog number is T124835 and the CAS number is 4532-33-6.</p>Formula:C14H13NOColor and Shape:SolidMolecular weight:211.264Rineterkib hydrochloride
CAS:<p>Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.</p>Formula:C26H28BrClF3N5O2Color and Shape:SolidMolecular weight:614.89Pan-RAS-IN-7
CAS:<p>Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.</p>Formula:C59H76N8O8Color and Shape:SolidMolecular weight:1025.28NUCC-0200808
<p>NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.</p>Color and Shape:Odour SolidPROTAC SOS1 degrader-1
CAS:<p>PROTAC SOS1 degrader-1: potent, DC50 98.4 nM, inhibits KRAS mutant cancer cells, low-toxic antitumor.</p>Formula:C57H76O4ClFN10SColor and Shape:SoildMolecular weight:1050.54443KRASG12C IN-14
<p>KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.</p>Formula:C51H65F4N9O9S2Color and Shape:SolidMolecular weight:1088.24HPK1-IN-39
<p>HPK1-IN-39 (Compound 10n), a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) with an inhibitory concentration (IC50) of 29 nM, impedes the</p>Formula:C26H27N7O2Color and Shape:SolidMolecular weight:469.54KRAS inhibitor-33
<p>KRAS inhibitor-33 (compound 115a) is a pyrido[2,3-d]pyrimidine derivative that serves as an effective inhibitor of KRAS, exhibiting an IC50 value of ≤ 100nM.</p>Formula:C33H39ClF2N6O3Color and Shape:SolidMolecular weight:641.15MRTF-A-IN-2
<p>MRTF-A-IN-2 (compound 16) is an inhibitor of MRTF-A. It effectively suppresses cell proliferation and induces senescence in HCC cells.</p>Color and Shape:Odour SolidSS47
CAS:<p>SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.</p>Formula:C49H56N6O12SColor and Shape:SolidMolecular weight:953.07BAS 00489700
CAS:<p>BAS 00489700 is a N-UTR interaction inhibitor. BAS 00489700 inhibits virus replication in cell culture.</p>Formula:C19H16N2O4Purity:99.78%Color and Shape:SolidMolecular weight:336.34KRAS G12D inhibitor 7
CAS:<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Formula:C32H38N8O3Color and Shape:SolidMolecular weight:582.709(S)-BAY-293
CAS:<p>(S)-BAY-293 is a potent pan-KRAS inhibitor for the study of primary non-small lung and pancreatic cancers.</p>Formula:C25H28N4O2SPurity:98%Color and Shape:SolidMolecular weight:448.58PDE4-IN-26
<p>PDE4-IN-26 (Compound A5) is an orally active, highly selective inhibitor of PDE4. It exhibits anti-inflammatory properties by inhibiting p38 MAPK phosphorylation. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 reduces lung inflammation, damage, and fibrosis, while promoting sputum secretion and alleviating cough. It is useful for researching lung injury-related diseases.</p>Formula:C22H18F2N4O3SColor and Shape:SolidMolecular weight:456.47LYMTAC-2
<p>LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.</p>Color and Shape:SolidMolecular weight:1248.44Mitogen-activated protein kinase 1
CAS:<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Purity:98%Color and Shape:SolidJNK3 inhibitor-7
<p>Potent, oral JNK3 inhibitor-7 crosses blood-brain barrier, IC50: 53 nM (JNK3), offers neuroprotection, potential in AD research.</p>Formula:C32H31N7O3Color and Shape:SolidMolecular weight:561.63
